STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity

Combining different immunotherapy approaches is currently building the future of immunotherapy, with the view to maximize anti-tumoral efficacy for larger patient population. The KISIMA™ platform allows the development of protein-based cancer vaccines able to induce tumor-specific T cell response re...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Matteo, Carboni, Susanna, Di Berardino-Besson, Wilma, Riva, Erika, Santiago-Raber, Marie-Laure, Belnoue, Elodie, Derouazi, Madiha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283310/
https://www.ncbi.nlm.nih.gov/pubmed/34276686
http://dx.doi.org/10.3389/fimmu.2021.695056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283310/
https://www.ncbi.nlm.nih.gov/pubmed/34276686
http://dx.doi.org/10.3389/fimmu.2021.695056

Ejemplares similares